Nektar Therapeutics (NKTR) vs Trevi Therapeutics, Inc. (TRVI)
Nektar Therapeutics and Trevi Therapeutics, Inc. are both Biotechnology companies. Nektar Therapeutics and Trevi Therapeutics, Inc. are of similar size ($2.1B and $2.1B). Trevi Therapeutics, Inc. has the higher net margin (0.00% vs −287.8%) and the lower return on invested capital (−1,412.1% vs −40.2%). Across the 13 metrics below, Trevi Therapeutics, Inc. leads on 9 and Nektar Therapeutics on 4.
Valuation
Profitability
| Metric | NKTR | TRVI | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 0.00% | 65.16% |
| Operating margin | (257.80%) | 0.00% | 0.00% |
| Net margin | (287.84%) | 0.00% | 0.00% |
| Free cash flow margin | (428.72%) | 0.00% | 0.00% |
| Return on equity | (35.75%) | (19.66%) | (57.72%) |
| Return on assets | (24.12%) | (18.97%) | (49.22%) |
| Return on invested capital | (40.20%) | (1,412.11%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack